Viridian Therapeutics, Inc.\DE

This biopharmaceutical company focuses on discovering, developing, and commercializing targeted therapies for serious autoimmune and rare conditions. Its research and clinical pipeline centers on therapeutic candidates addressing validated biological pathways, notably thyroid eye disease and related autoimmune indications. The company's core development programs feature anti-insulin-like growth factor 1 receptor product candidates, including the intravenous monoclonal antibody veligrotug and subcutaneous elegrobart. In addition, its pipeline includes neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008, alongside a thyroid-stimulating hormone receptor inhibitor program. Its end users are patients suffering from debilitating rare diseases, with commercial outreach targeting physicians and healthcare payors.

The business manages global clinical programs across international study locations, including trials throughout the United States. It maintains worldwide commercial rights for its leading product candidates, excluding Japan and greater China, where commercialization and development rights have been out-licensed to regional corporate partners. The provided excerpt does not state the company's headquarters location.

Summary of the business section of Viridian Therapeutics, Inc.\DE's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 252 full-time employees located in the U.S., including at our facilities in Waltham, Massachusetts and Boulder, Colorado.”